HIGHLIGHTS
- who: Acute myelogenous leukemia (AML) from the College of Materials and Chemical Engineering, Chuzhou University, Chuzhou, China have published the article: Cytarabine delivered by CD44 and bone targeting redox-sensitive liposomes for treatment of acute myelogenous leukemia, in the Journal: (JOURNAL) of May/30,/2022
- what: In this study, the redox-sensitive liposomes targeting the bone and CD44 were developed for the treatment of AML.
- how: The results showed that the bone-targeting liposomes treatment increased BMC and BV/TV compared to non-targeting liposomes. The results indicated that the liposomes with -SS . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.